In vitro activity of a new polyene, SPA-S-843, against yeasts

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 3012-3013

  Rimaroli, C ^a   Bruzzese, T ^a  

^a Societa Prodotti Antibiotici SpA ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; N DIMETHYLMINOACETYL PARTRICIN A 2 DIMETHYLAMINOETHYLAMIDE DIASCORBIC ACID; POLYENE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CRYPTOCOCCUS NEOFORMANS; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; YEAST;

EID: 0031756586     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.3012     Document Type: Article

References (19)

1. Anaisse, E. J., G. P. Bodey, and M. G. Rinaldi. 1989. Emerging fungal pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 8:323-330.
2. Bonabello, A., and T. Bruzzese. 1997. Antifungal activity of SPA-S-843, in comparison with amphotericin B and fluconazole, on murine experimental infections, abstr. P-89, p. 137. In Abstracts of trends in invasive fungal infections 4, Barcelona, Spain.
3. Cameron, M. L., W. A. Schell, S. Bruch, J. A. Bartlett, H. A. Waskin, and J. R. Perfect. 1993. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms in individuals seropositive for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 37: 2449-2453.
4. Fung-Tomc, J. C., B. Minassian, E. Huczko, B. Kolek, D. P. Bonner, and R. E. Kessler. 1995. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob. Agents Chemother. 39:295-300.
5. Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. 41:180-183.
6. Hadfield, T. L., M. B. Smiths, R. E. Winn, M. G. Rinaldi, and C. Guerra. 1987. Mycoses caused by Candida lusitaniae. Rev. Infect. Dis. 9:1006-1012.
7. Hitchcock, C. A., G. W. Pye, P. F. Troke, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37: 1962-1965.
8. Lozano-Chiu, M., J. H. Rex, and P. W. Nelson. 1996. Lot-to-lot variability of antibiotic medium 3 (AM3) when used for susceptibility testing of Candida to amphotericin B (AmB) by M27P, abstr. F-84, p. 88. In Abstracts of the 96th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
9. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Pfaller, M. A. 1989. Infection control: opportunistic fungal infection - the increasing importance of Candida species. Infect. Control Hosp. Epidemiol. 9:408-416.
11. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinell-Ingroff, J. H. Rex, and M. G. Rinaldi. 1994. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J. Clin. Microbiol. 32:1650-1653.
12. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinell-Ingroff, J. H. Rex, M. G. Rinaldi, C. R. Cooper, and M. R. McGinnis. 1995. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J. Clin. Microbiol. 33:1104-1107.
13. Pfaller, M. A., and R. Wenzel. 1992. Impact of the changing epidemiology of fungal infections in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis. 11:287-291.
14. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalberg, and M. Pfaller. 1994. Development of resistance to fluconazole among isolates of Candida albicans obtained during treatment of oropharyngeal candidiasis in AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
15. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39:906-909.
16. Sabra, R., and R. A. Branch. 1990. Amphotericin B nephrotoxicity. Drug Saf. 5:94-108.
17. Shadomy, S., and M. A. Pfaller. 1991. Laboratory studies with antifungal agents: susceptibility tests and quantitation in body fluids, p. 1173-1183. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
18. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522.
19. Wenzel, R. P., and M. A. Pfaller. 1991. Candida species: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Infect. Control Hosp. Epidemiol. 12:523-524.